These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21969518)

  • 21. Development of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat.
    Timchalk C; Poet TS
    Neurotoxicology; 2008 May; 29(3):428-43. PubMed ID: 18394709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Malathion bioactivation in the human liver: the contribution of different cytochrome p450 isoforms.
    Buratti FM; D'Aniello A; Volpe MT; Meneguz A; Testai E
    Drug Metab Dispos; 2005 Mar; 33(3):295-302. PubMed ID: 15557345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
    Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
    Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism of Delta(3)-carene by human cytochrome p450 enzymes: identification and characterization of two new metabolites.
    Duisken M; Benz D; Peiffer TH; Blömeke B; Hollender J
    Curr Drug Metab; 2005 Dec; 6(6):593-601. PubMed ID: 16379671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor.
    Kassahun K; McIntosh IS; Shou M; Walsh DJ; Rodeheffer C; Slaughter DE; Geer LA; Halpin RA; Agrawal N; Rodrigues AD
    Drug Metab Dispos; 2001 Jun; 29(6):813-20. PubMed ID: 11353749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of the human liver microsomal cytochrome P450s involved in the metabolism of N-nitrosodi-n-propylamine.
    Teiber JF; Hollenberg PF
    Carcinogenesis; 2000 Aug; 21(8):1559-66. PubMed ID: 10910959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood cholinesterases as human biomarkers of organophosphorus pesticide exposure.
    Nigg HN; Knaak JB
    Rev Environ Contam Toxicol; 2000; 163():29-111. PubMed ID: 10771584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man?
    Mutch E; Daly AK; Leathart JB; Blain PG; Williams FM
    Arch Toxicol; 2003 Jun; 77(6):313-20. PubMed ID: 12669189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human cytochrome P450-catalyzed conversion of the proestrogenic pesticide methoxychlor into an estrogen. Role of CYP2C19 and CYP1A2 in O-demethylation.
    Stresser DM; Kupfer D
    Drug Metab Dispos; 1998 Sep; 26(9):868-74. PubMed ID: 9733665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of the cytochrome P450 isoenzymes involved in the metabolism of diazinon in the rat liver.
    Fabrizi L; Gemma S; Testai E; Vittozzi L
    J Biochem Mol Toxicol; 1999; 13(1):53-61. PubMed ID: 9890448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
    Chimalakonda KC; Seely KA; Bratton SM; Brents LK; Moran CL; Endres GW; James LP; Hollenberg PF; Prather PL; Radominska-Pandya A; Moran JH
    Drug Metab Dispos; 2012 Nov; 40(11):2174-84. PubMed ID: 22904561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals.
    Usmani KA; Cho TM; Rose RL; Hodgson E
    Drug Metab Dispos; 2006 Sep; 34(9):1606-14. PubMed ID: 16790556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro age-dependent enzymatic metabolism of chlorpyrifos and chlorpyrifos-oxon in human hepatic microsomes and chlorpyrifos-oxon in plasma.
    Smith JN; Timchalk C; Bartels MJ; Poet TS
    Drug Metab Dispos; 2011 Aug; 39(8):1353-62. PubMed ID: 21521795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contribution of carboxylesterase and cytochrome P450 to the bioactivation and detoxification of isocarbophos and its enantiomers in human liver microsomes.
    Zhuang XM; Wei X; Tan Y; Xiao WB; Yang HY; Xie JW; Lu C; Li H
    Toxicol Sci; 2014 Jul; 140(1):40-8. PubMed ID: 24752505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
    Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
    Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro identification of the cytochrome P450 isozymes involved in the N-demethylation of the active opioid metabolite nortilidine to bisnortilidine.
    Wustrow I; Riedel KD; Mikus G; Weiss J
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Jun; 385(6):633-9. PubMed ID: 22349139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increasing uptake and bioactivation with development positively modulate diazinon toxicity in early life stage medaka (Oryzias latipes).
    Hamm JT; Wilson BW; Hinton DE
    Toxicol Sci; 2001 Jun; 61(2):304-13. PubMed ID: 11353139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Examination of purported probes of human CYP2B6.
    Ekins S; VandenBranden M; Ring BJ; Wrighton SA
    Pharmacogenetics; 1997 Jun; 7(3):165-79. PubMed ID: 9241656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel approaches to mitigating parathion toxicity: targeting cytochrome P450-mediated metabolism with menadione.
    Jan YH; Richardson JR; Baker AA; Mishin V; Heck DE; Laskin DL; Laskin JD
    Ann N Y Acad Sci; 2016 Aug; 1378(1):80-86. PubMed ID: 27441453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ciprofol is primarily glucuronidated by UGT1A9 and predicted not to cause drug-drug interactions with typical substrates of CYP1A2, CYP2B6, and CYP2C19.
    Hou L; Zhao Y; Zhao S; Zhang X; Yao X; Yang J; Wang Z; Chan ECY; Liu S
    Chem Biol Interact; 2024 Jan; 387():110811. PubMed ID: 37993078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.